Last-Hope drug offered to patients with advanced blood cancer
NCT ID NCT05164250
Summary
This program provides access to an investigational drug called REGN5458 for patients with advanced multiple myeloma who have exhausted all approved treatments. It is a 'compassionate use' program, meaning it is for individual patients in urgent need, not a formal clinical trial. The goal is to see if the drug can help control the cancer when no other options are available.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.